Restenosis - Pipeline Review, H2 2012

Report Overview

Table of Contents

1323.1

Select License Type

£1,323.10	Electronic License Electronic License An electronic version (mostly PDF, but can be Excel or PPT), which is either available for immediate download or will be sent via email by the Publisher of the report. The licencing for an electronic version is for use by the purchaser ONLY.
£2,646.20	Site License Site License An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is intended for use by more than one individual, across for example, a site, an office, or a division or country.
£3,969.30	Corporate License Corporate License An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is/are intended for use by an organisation in its entirety. For example, if reports are put on an Intranet or if they are distributed or used by more than one office, division, or country operation, then a Corporate Licence is required.

£1,323.10	Add to Wishlist
Change Currency	GBP EURO USD
	Order By Fax

Market	Healthcare and Medical
Report Type	Market Research
Country	Global
Published	25 November 2012
Number of Pages	78
Report Delivery	Email
Delivery Lead Time	1-3 hours, 24 hour max
Publisher	Global Markets Direct
File Format	PDF

Restenosis - Pipeline Review, H2 2012 - This report 'Restenosis - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Restenosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Restenosis. Restenosis - Pipeline Review, Half Year is built using data and information sourced from our proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Restenosis.
- A review of the Restenosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Restenosis pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Restenosis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Restenosis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Speak to an Advisor

Call us on
+44 (0) 203 086 8600

Select License Type

£1,323.10	Electronic License Electronic License An electronic version (mostly PDF, but can be Excel or PPT), which is either available for immediate download or will be sent via email by the Publisher of the report. The licencing for an electronic version is for use by the purchaser ONLY.
£2,646.20	Site License Site License An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is intended for use by more than one individual, across for example, a site, an office, or a division or country.
£3,969.30	Corporate License Corporate License An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is/are intended for use by an organisation in its entirety. For example, if reports are put on an Intranet or if they are distributed or used by more than one office, division, or country operation, then a Corporate Licence is required.

£1,323.10	Add to Wishlist
Change Currency	GBP EURO USD

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Restenosis Overview
Therapeutics Development
An Overview of Pipeline Products for Restenosis
Restenosis Therapeutics under Development by Companies
Restenosis Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Restenosis Therapeutics – Products under Development by Companies
Restenosis Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Restenosis Therapeutics Development
Mesoblast Ltd
Novogen Limited
Bio3 Research S.r.l
AnGes MG, Inc.
Resverlogix Corp.
CytoTools AG
Angelini Group
ProtAffin Biotechnologie AG
Amalyte Pharmaceuticals, LLC
Pervasis Therapeutics, Inc.
AIM Therapeutics Inc.
Athera Biotechnologies AB
miRagen Therapeutics, Inc.
XBiotech USA, Inc.
Restenosis – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
CT-406 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NV-27 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AM-1101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HMW-02Ap - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AIM-501 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NFkappaB Decoy Oligodeoxynucleotide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PVS-10200 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bindarit - Drug Profile
Product Description
Mechanism of Action
R&D Progress
prednisone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug Targeting Plasminogen Activator Inhibitor Type 1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PC-mAb - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CV-18C3 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MCP-1 Program - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MGN-2677 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Butylphthalide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
paclitaxel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
UrinaryKallidinogenase - Drug Profile
Product Description
Mechanism of Action
R&D Progress
COR-3 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Compound For Drug Eluting Stent - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ReVas Program - Drug Profile
Product Description
Mechanism of Action
R&D Progress
paclitaxel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VAN 10-4 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Restenosis Therapeutics – Drug Profile Updates
Restenosis Therapeutics – Discontinued Products
Restenosis Therapeutics - Dormant Products
Restenosis – Product Development Milestones
Featured News & Press Releases
Aug 18, 2011: XBiotech Announces Initiation Of Restenosis Clinical Trial In All Five US Sites
Dec 22, 2010: XBiotech Files IND For CV-18C3 Monoclonal Antibody Therapy To Treat Peripheral Vascular Disease
Apr 07, 2010: Pervasis Starts Second Clinical Program Targeting Peripheral Arterial Disease
Mar 22, 2010: ChemoCentryx Announces Phase II Clinical Trial of CCX140 For Type 2 Diabetes And Vascular Restenosis
Jan 29, 2010: Bindarit A MCP-1/CCL2 Production Inhibitor
Apr 15, 2009: AnGes MG Receives Japanese Substance Patent For NF-kB Decoy Oligonucleotide
Mar 17, 2008: BioSyntech Announces Positive Preliminary Interim Data For BST-CarGel Clinical Trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products Under Development for Restenosis, H2 2012
Products under Development for Restenosis – Comparative Analysis, H2 2012
Number of Products under Development by Companies, H2 2012
Number of Products under Development by Companies, H2 2012 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2012
Comparative Analysis by Late Stage Development, H2 2012
Comparative Analysis by Mid Clinical Stage Development, H2 2012
Comparative Analysis by Early Clinical Stage Development, H2 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012
Products under Development by Companies, H2 2012
Products under Investigation by Universities/Institutes, H2 2012
Mesoblast Ltd, H2 2012
Novogen Limited, H2 2012
Bio3 Research S.r.l, H2 2012
AnGes MG, Inc., H2 2012
Resverlogix Corp., H2 2012
CytoTools AG, H2 2012
Angelini Group, H2 2012
ProtAffin Biotechnologie AG, H2 2012
Amalyte Pharmaceuticals, LLC, H2 2012
Pervasis Therapeutics, Inc., H2 2012
AIM Therapeutics Inc., H2 2012
Athera Biotechnologies AB, H2 2012
miRagen Therapeutics, Inc., H2 2012
XBiotech USA, Inc., H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Stage and Molecule Type, H2 2012
Restenosis Therapeutics – Drug Profile Updates
Restenosis Therapeutics – Discontinued Products
Restenosis Therapeutics – Dormant Products

List of Figures

Number of Products under Development for Restenosis, H2 2012
Products under Development for Restenosis – Comparative Analysis, H2 2012
Products under Development by Companies, H2 2012
Products under Investigation by Universities/Institutes, H2 2012
Late Stage Products, H2 2012
Mid Clinical Stage Products, H2 2012
Early Clinical Stage Products, H2 2012
Discovery and Pre-Clinical Stage Products, H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Route of Administration, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Molecule Type, H2 2012
Assessment by Stage and Molecule Type, H2 2012 39

Visitor Comments

All Comments

Change Currency

GBP

EURO

USD

Last Viewed

Restenosis - Pipeline Review, H2 2012

Healthcare and Medical Company Profiles

Find latest Healthcare and Medical Company Profiles with up to date financial, strategic, operational, SWOT analysis and product information for the leading healthcare and medical companies.

Competitor Tracking

Do you need to track your competitors and customers on a continuous basis? We have the expertise to provide you with a cost-effective, fully customised competitor tracking portal, which collates data on your competitors on a continuous basis. Contact us for a free consultation and demonstration.

Become an Affiliate

Do you manage an industry specific website or blog? Are you looking to monetise your web traffic further? Are you a B2B website?

Why not offer your visitors industry specific strategic market reports and company profiles? Our Affiliate Program enables you to provide quality content on your website and to earn money from passing on visitors to our website.

Custom Research

Cannot find what you need? We can tailor a report for you. Complete the Custom Research Form and we will provide a quote.

Healthcare and Medical	Type	Keywords Phrase All Words Any Word
Microsoft Windows users can hold the CTRL Key to select more than one sector or country at a time. Apple users can hold the CMD Key to do the same.	Country	Industry Sector
Publisher	Order By Relevance Date	Published In

Restenosis - Pipeline Review, H2 2012

Select License Type

Speak to an Advisor

Select License Type

Table of Contents

Visitor Comments

Change Currency

Last Viewed

Healthcare and Medical Company Profiles

Competitor Tracking

Become an Affiliate

Custom Research

News

Market Insights

Companies And Markets

Customer Support

Corporate Accounts

Contact Details

Contrast settings

Text size settings

All
Afghanistan
Africa
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antigua and Barbuda
Argentina
Armenia
Aruba
Asia
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia-Herzegovina
Botswana
Bouvet Island
Brazil
British Virgin Islands
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Caribbean
Cayman Islands
Central African Republic
Central America
Central Europe
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Conch Republic
Cook Islands
Costa Rica
Croatia
Cuba
Cyprus
Czech Republic
Democratic Republic of the Congo
Denmark
Djibouti
Dominica
Dominican Republic
Eastern Europe
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Europe
Falkland Islands
Faroe Islands
Fiji
Finland
France
French Guiana
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Global
Greece
Greenland
Grenada
Guadeloupe (French)
Guam (USA)
Guatemala
Guernsey
Guinea
Guinea Bissau
Guyana
Haiti
Heard Island and McDonald Islans
Holy See
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran
Iraq
Ireland
Israel
Italy
Ivory Coast
Ivory Coast (Cote D`Ivoire)
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Kurdistan
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macau
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique (French)
Mauritania
Mauritius
Mayotte
Mexico
Micronesia
Middle East
Moldova
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
Netherlands Antilles
New Caledonia (French)
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
North America
North Korea
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn Island
Poland
Polynesia (French)
Portugal
Puerto Rico
Qatar
Republic of the Congo
Reunion
Romania
Russia
Rwanda
Saint Barthelemy
Saint Helena
Saint Kitts and Nevis
Saint Lucia
Saint Martin
Saint Pierre and Miquelon
Saint Vincent and Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Scandinavia
Schengen countries
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South America
South Georgia and the South Sandwich Islands
South Korea
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen Islands
Swaziland
Sweden
Switzerland
Syria
Taiwan
Tajikistan
Tanzania
Thailand
Timor-Leste (East Timor)
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela
Vietnam
Virgin Islands
Wallis and Futuna Islands
Western Sahara
Yemen
Zambia
Zimbabwe

All
Aerospace
Agriculture, Farming & Raw Materials
Automotive and Parts
Business Services
Chemicals
Construction
Consumer Goods
Defence
Energy and Utilities
Environmental
Finance and Banking
Food and Drink
Healthcare and Medical
Industrial
Information Technology
Leisure
Logistics
Media
Paper and Packaging
Publishing and Printing
Real Estate
Retail
Security
Telecommunications
Textiles and Clothing
Transportation
Travel